{"id":"W4392739578","doi":"10.1038/s41467-024-46495-2","title":"PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Susan G. Komen; Cancer Prevention and Research Institute of Texas; Welch Foundation; National Cancer Institute; U.S. Department of Health and Human Services; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Protein arginine methyltransferase 5; Cancer research; Fulvestrant; Retinoblastoma protein; Breast cancer; Downregulation and upregulation; Palbociclib; Biology; Estrogen receptor; Cancer; Cell cycle; Methyltransferase; Metastatic breast cancer; Biochemistry; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001658984,0.0001461305,0.0001044517,0.0001174535,0.0001594547,0.00006664301,0.00045278,0.0003970842,0.00009129643],"category_scores_gemma":[0.00001073323,0.0001439097,0.00007495896,0.0004334517,0.0000857233,0.00001784036,0.0001546338,0.0005518142,0.00001274054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001846437,"about_ca_system_score_gemma":0.0002760919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001640272,"about_ca_topic_score_gemma":0.002348461,"domain_scores_codex":[0.9989938,0.0001007143,0.0002105203,0.0003381484,0.0001591898,0.0001976007],"domain_scores_gemma":[0.9985482,0.00002067976,0.00005102889,0.001193359,0.0001314577,0.00005534123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001608133,0.0004017111,0.002779089,0.00005826682,0.0001918447,0.000001468738,0.0006031335,0.002576785,0.9523966,0.004643343,0.02299321,0.01319373],"study_design_scores_gemma":[0.0004379362,0.00009313237,0.03439693,0.0001408367,0.00005537352,0.0000292507,0.000204078,0.008498544,0.03619152,0.0005661097,0.9189655,0.00042075],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6447923,0.3055224,0.0005308735,0.04057547,0.001861498,0.001175259,0.001011445,0.0002138878,0.004316888],"genre_scores_gemma":[0.9950076,0.002385408,0.0005231125,0.0004574781,0.000219543,0.0001205573,0.0004917208,0.0000345355,0.0007599943],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9162051,"threshold_uncertainty_score":0.5868466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314758869348883,"score_gpt":0.3076607452952672,"score_spread":0.2945131566017783,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}